Home > Publications database > Patterns and influencing factors of exercise attendance of breast cancer patients during neoadjuvant chemotherapy. > print

001     286662
005     20241127133736.0
024 7 _ |a 10.1007/s00520-023-08269-2
|2 doi
024 7 _ |a pmid:38170301
|2 pmid
024 7 _ |a 0941-4355
|2 ISSN
024 7 _ |a 1433-7339
|2 ISSN
024 7 _ |a altmetric:158191215
|2 altmetric
037 _ _ |a DKFZ-2024-00026
041 _ _ |a English
082 _ _ |a 610
100 1 _ |a Goldschmidt, Siri
|0 P:(DE-He78)f42e2297e771e17df08f2cc1171df9e4
|b 0
|e First author
|u dkfz
245 _ _ |a Patterns and influencing factors of exercise attendance of breast cancer patients during neoadjuvant chemotherapy.
260 _ _ |a New York,NY
|c 2024
|b Springer
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1704372577_7492
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
500 _ _ |a #EA:C110#LA:C110#
520 _ _ |a Performing 2-3 exercise sessions/week may relieve therapy-related side effects of breast cancer patients (BRCA) and improve their quality of life. However, attendance to the exercise sessions is often impaired. Thus, we investigated patterns and possible influencing factors of attendance to an aerobic (AT) or resistance training (RT) intervention in BRCA during neoadjuvant chemotherapy.BRCA (N = 122) were randomly allocated to supervised AT or RT twice weekly during neoadjuvant chemotherapy (18 ± 4 weeks). Attendance was calculated individually and group-wise per training week as the percentage of the performed sessions out of the prescribed sessions. Possible influencing factors were investigated using multiple regression analyses.Mean individual attendance was 44.1% ± 29.3% with no significant differences between the groups. Group-wise attendance was highest in the first 6 weeks of training with ≥ 60% for AT and ≥ 50% for RT, but decreased over the course of the intervention accompanying chemotherapy. Significantly higher attendance was associated with not having vs. having nausea (ß = - 14.57; p = 0.007) and not having vs. having pain (ß = - 12.07; p = 0.12), whereas fatigue did not show any association (ß = - 0.006; p = 0.96). Having been randomized into a preferred intervention group (48.8%) showed no association with attendance. Yet, patients' rating of the exercise intervention as 'good'/ 'very good' (58.7%) was significantly associated with higher attendance (p = 0.01).For both exercise interventions, group-wise attendance/training week decreased during chemotherapy despite good intervention ratings. While some patients never started, others trained almost constantly twice weekly. The study revealed that patients who are nauseous or experience pain may need more support to attend more exercise sessions. Trial Registration Clinicaltrials.gov: NCT02999074 from May 6, 2016.
536 _ _ |a 313 - Krebsrisikofaktoren und Prävention (POF4-313)
|0 G:(DE-HGF)POF4-313
|c POF4-313
|f POF IV
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
650 _ 7 |a Attendance
|2 Other
650 _ 7 |a Breast neoplasms
|2 Other
650 _ 7 |a Exercise intervention
|2 Other
650 _ 7 |a Neoadjuvant chemotherapy
|2 Other
700 1 _ |a Schmidt, Martina
|0 P:(DE-He78)2def8f8594c8f797f5ed4398258c6cac
|b 1
|u dkfz
700 1 _ |a Rosenberger, Friederike
|b 2
700 1 _ |a Wiskemann, Joachim
|b 3
700 1 _ |a Steindorf, Karen
|0 P:(DE-He78)a0c2037d9054be26907a05ae520d5756
|b 4
|e Last author
|u dkfz
773 _ _ |a 10.1007/s00520-023-08269-2
|g Vol. 32, no. 1, p. 79
|0 PERI:(DE-600)1463166-0
|n 1
|p 79
|t Supportive care in cancer
|v 32
|y 2024
|x 0941-4355
856 4 _ |u https://inrepo02.dkfz.de/record/286662/files/s00520-023-08269-2.pdf
856 4 _ |u https://inrepo02.dkfz.de/record/286662/files/s00520-023-08269-2.pdf?subformat=pdfa
|x pdfa
909 C O |o oai:inrepo02.dkfz.de:286662
|p VDB
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 0
|6 P:(DE-He78)f42e2297e771e17df08f2cc1171df9e4
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 1
|6 P:(DE-He78)2def8f8594c8f797f5ed4398258c6cac
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 4
|6 P:(DE-He78)a0c2037d9054be26907a05ae520d5756
913 1 _ |a DE-HGF
|b Gesundheit
|l Krebsforschung
|1 G:(DE-HGF)POF4-310
|0 G:(DE-HGF)POF4-313
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Krebsrisikofaktoren und Prävention
|x 0
914 1 _ |y 2024
915 _ _ |a DEAL Springer
|0 StatID:(DE-HGF)3002
|2 StatID
|d 2023-10-21
|w ger
915 _ _ |a DEAL Springer
|0 StatID:(DE-HGF)3002
|2 StatID
|d 2023-10-21
|w ger
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2023-10-21
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2023-10-21
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2023-10-21
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2023-10-21
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2023-10-21
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2023-10-21
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1110
|2 StatID
|b Current Contents - Clinical Medicine
|d 2023-10-21
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b SUPPORT CARE CANCER : 2022
|d 2023-10-21
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0600
|2 StatID
|b Ebsco Academic Search
|d 2023-10-21
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b ASC
|d 2023-10-21
915 _ _ |a IF < 5
|0 StatID:(DE-HGF)9900
|2 StatID
|d 2023-10-21
920 2 _ |0 I:(DE-He78)C110-20160331
|k C110
|l Bewegung, Präventionsforschung und Krebs
|x 0
920 1 _ |0 I:(DE-He78)C110-20160331
|k C110
|l Bewegung, Präventionsforschung und Krebs
|x 0
920 0 _ |0 I:(DE-He78)C110-20160331
|k C110
|l Bewegung, Präventionsforschung und Krebs
|x 0
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-He78)C110-20160331
980 _ _ |a UNRESTRICTED

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21